Efficacy of anti‐CD3 monoclonal antibodies in delaying the progression of recent‐onset type 1 diabetes mellitus: A systematic review, meta‐analyses and meta‐regression
Pooled result · C-peptide AUCResult — go to the resultMean difference 0.114 95% CI 0.069–0.159Authors' conclusion
The findings of this review suggest that anti-CD3 monoclonal antibody treatment increases endogenous insulin production and improves the lifestyle of patients by reducing insulin dosage. Future studies should consider the limitations, including sample size, heterogeneity and duration of follow-up, to validate the generalizability of these findings further.
Study context
- Population
- Recent-onset T1D; mean age 15 years; mean follow-up 2.04 years
- Participants
- 1,397 participants11 RCTs
- Comparison
- Anti-CD3 monoclonal antibodies vs placebo
- Anti-CD3 monoclonal antibodiesn = 908
- Placebon = 489reference
- Outcome
- C-peptide AUC
- Follow-up
- Shorter timeframes
Methodological detailsrandom-effects model, meta-regression, Cochrane risk of bias tool
- Random-effects model
- Meta-regression
- Cochrane risk of bias tool
Pooled result
As reported in the abstract
Mean difference
0.114
95% CI 0.069–0.159
P = 0.000
Anti-CD3 monoclonal antibodiesvs Placebo
mean difference 0.114 (95% CI 0.069–0.159); P = 0.000
Further pooled results
| Outcome | Mean difference (95% CI) | P value | |
|---|---|---|---|
| Insulin intake · all timeframesReduced with anti-CD3 | −0.123 (−0.151 to −0.094) | P < 0.001 | |
| −0.2−0.100.1Difference (linear scale) |
HbA1c
- No significant effect on HbA1c
Original publication
Efficacy of anti‐CD3 monoclonal antibodies in delaying the progression of recent‐onset type 1 diabetes mellitus: A systematic review, meta‐analyses and meta‐regression. Diabetes Obes Metab. Published 14 August 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →